Knowledge.

Dear Shareholders


It is only natural, in the light of our Directors seeming haste to sell out the Company, for investors to be asking the question "Do they know something [bad] that we don't"


Frankly, that is extremely unlikely for a number of reasons.


Even though Cellestis is currently subject to a proposed takeover via a Scheme of Arrangement, it is important to understand that Cellestis is still a listed Company on the ASX. The Shares in the Company are still trading on the ASX. This means that the Company must continue to abide by the ASX listing rules.


The Company must continue to meet the requirements of ASX Listing Rule 3.1 (Continuous Disclosure) to keep the market informed of material events as they occur.


At the 2010 AGM in November 2010 CST advised

"Revenue growth of between 30% and 40% is expected for full fiscal year 2011.. ..our goal in financial year 2012 is to achieve similar revenue growth as this fiscal year."

They also provided the following Growth Outlook

"Sales of ~1.9 Million tests in FY2010. Estimated sales of between 2.6 Million and 2.9 Million in FY2011"

As Shareholders, we are entitled to use these statements to make decisions about our investment in Cellestis and the Directors of Cellestis would be aware that we would have done so.


If any of these statements are now materially incorrect then the Company, under ASX listing rules, must inform us of that.


They have not done so and unless they were to do so we are entitled to believe that those statements still stand.


It is self evident that Qiagen propose to purchase Cellestis in the belief that Sales of QuantiFERON will continue to grow. In fact, in their own PRESENTATION to their shareholders, they point to "double digit growth" of QuantiFERON sales in 2011 and "substantial double digit growth" in 2012.


Qiagen, of course, are privvy to much information about our Company that we are not. It seems clear that, with access to that information, they agree with us that the sales of QuantiFERON are growing rapidly and will continue to do so.


Given all of this, we can be confident that there is no reason not to believe that the future of QuantiFERON (and Cellestis) has all of the potential that we have long believed in. There are no facts to contradict this.


Vic Bula


Spokesperson


Cellestis Shareholders Action Group